MedTrace Logo

Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)

NCT01318330 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-07-19

No results posted yet for this study

Summary

Official Title: Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH after Intra Venus Administration for the Treatment of Graft versus Host Disease Patients

Sponsor: HomeoTherapy Co.,Ltd

Study Design: Single Group, Open Label, 5 Week, Safety Study

This study is designed to evaluate the safety of ex-vivo cultured adult human clonal mesenchymal stem cells (cMSC) derived from human bone marrow in subjects experiencing acute or chronic graft-versus-host disease (GVHD).

Study Type: Interventional

Conditions

  • Graft-vs-Host Disease

Interventions

DRUG

Homeo-GH

Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)

Sponsors & Collaborators

  • HomeoTherapy Co., Ltd

    lead INDUSTRY

Principal Investigators

  • SunUk Song, Ph.D. · Inha Univ. College of Medicine

  • Charles, JH Kim, Ph.D. · HomeoTherapy Co., Ltd

  • Hyun Gyu Lee, M.D.,Ph.D. · Inha Univerisity Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-12-31
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318330 on ClinicalTrials.gov